A United Kingdom buyer, with 8 published contracts, most recently 6 months ago.
This contract opportunity involves the establishment of non-exclusive discount agreements for finished medicines containing the active ingredients Tramadol and Paracetamol (ATC: N02AJ13) under an 'open-house model'. All eligible and interested pharmaceutical companies or consortia are invited to ent
This contract opportunity involves the establishment of non-exclusive discount agreements for finished medicines containing the active ingredient Nilotinib (ATC: L01EA03) under an 'open-house model'. All eligible and interested pharmaceutical companies or consortia are invited to enter into or join
This publication is about entering into non-exclusive discount contracts according to § 130c Abs. 1 SGB V in conjunction with § 130a Abs. 8 SGB V for finished medicinal products containing the active ingredients Glecaprevir and Pibrentasvir (ATC: J05AP57) as part of an "open-house model". Under unif
This contract opportunity involves the establishment of non-exclusive discount agreements for finished pharmaceuticals containing the active ingredient Axitinib (ATC: L01EK01) under an 'open-house model'. All eligible and interested pharmaceutical companies or consortia are invited to enter into or
